Frovatriptan: A Review of Pharmacology, Pharmacokinetics and Clinical Potential in the Treatment of Menstrual Migraine

Figures & data

Figure 1 Structure of frovatriptan.

Table 1 Pharmacokinetics of frovatriptan in healthy male and female volunteers (age 18–45 years). Data obtained after a single oral dose of frovatriptan 2.5mg (Buchan et al 2002)

Gender	AUC (ng/h/mL)	Tmax(hr)	Cmax (ng/mL)	T1/2 (hr)	F (%)
Male	42.9	2.3	4.23	27.4	22.1
Female	94.0	3.0	7.0	25.7	29.6

Abbreviations: AUC, area under the plasma concentration-versus-time curve; C_max, peak plasma concentration; F, bioavailability; T_1/2, plasma half-life; T_max, time to reach peak plasma concentration.

BuchanPKeywoodCWadeAClinical pharmacokinetics of frovatriptanHeadache200242Suppl 2S546212028321

 PubMed Web of Science ®Google Scholar